Intravenous sulbactam/ampicillin in the treatment of pediatric infections

Lee, Chin‐Yun; Lin, Tsou-Yien; Chu, Mong-Ling; Lee, Ming-Jenn; Hsu, Ching-Ying; Huang, Li‐Min; Chen, Chong-Ming

doi:10.1016/0732-8893(89)90133-8

“…Introduced for clinical use during the past two decades, these agents, which include ampicillin/sulbactam, cefoperazone/sulbactam, amoxicillin/clavulanic acid, ticarcillin/clavulanic acid and piperacillin/tazobactam, have proved effective against both gram-positive and gram-negative infections, including those caused by organisms resistant to conventional ␤-lactam agents [21][22][23].…”

Section: Resistance To ␤-Lactam/ ␤-Lactamase Inhibitor Combinationsmentioning

confidence: 99%

The Importance ofβ-Lactamase Resistance in Surgical Infections

Edmiston¹,

Hennen

²

,

Seabrook³

2001

Surgical Infections

1

0

View full text Add to dashboard Cite

Substantial costs are associated with the treatment of nosocomial infections, 2 million cases of which occur annually in the United States. Hospital-acquired, gram-negative infection has become an increasing problem, particularly in the intensive care unit where up to 40% of the most frequently isolated strains of Enterobacteriaceae are resistant to standard beta-lactam antibiotics. Among several mechanisms of acquisition of resistance, beta-lactamase production accounts for a high percentage of treatment failures and relapses. By the end of the 1980s, some 10-30% of all nosocomial infections were caused by type-1 beta-lactamase-producing gram-negative isolates, and Enterobacter species had emerged as a major resistant pathogen. The beta-lactam/beta-lactamase inhibitor combinations, such as ampicillin/sulbactam, represent an innovative approach to the problem of beta-lactamase-mediated resistance. Clinical use of these agents has been associated with low rates of resistance and new data suggest they may have a specific role in controlling the emergence and spread of nosocomial infections.

show abstract

The Importance of -Lactamase Resistance in Surgical Infections

Edmiston¹,

Hennen²,

Seabrook³

2001

View full text Add to dashboard Cite

Substantial costs are associated with the treatment of nosocomial infections, 2 million cases of which occur annually in the United States. Hospital-acquired, gram-negative infection has become an increasing problem, particularly in the intensive care unit where up to 40% of the most frequently isolated strains of Enterobacteriaceae are resistant to standard beta-lactam antibiotics. Among several mechanisms of acquisition of resistance, beta-lactamase production accounts for a high percentage of treatment failures and relapses. By the end of the 1980s, some 10-30% of all nosocomial infections were caused by type-1 beta-lactamase-producing gram-negative isolates, and Enterobacter species had emerged as a major resistant pathogen. The beta-lactam/beta-lactamase inhibitor combinations, such as ampicillin/sulbactam, represent an innovative approach to the problem of beta-lactamase-mediated resistance. Clinical use of these agents has been associated with low rates of resistance and new data suggest they may have a specific role in controlling the emergence and spread of nosocomial infections.

show abstract